Pfizer Discloses 2026 Financial Results in SEC Filing

New York-based pharmaceutical company Pfizer Inc submitted a Form 8-K to the Securities and Exchange Commission on May 5, 2026, under accession number 0000078003-26-000053. The filing, assigned a score of 7 and flagged on the watchlist, addresses Item 2.02 for results of operations and financial condition, and Item 9.01 for financial statements and exhibits.

Pfizer, with Central Index Key 0000078003 and ticker symbol PFE, operates as a global biopharmaceutical firm serving millions of patients worldwide through its portfolio of medicines, vaccines, and consumer healthcare products. The company's financial disclosures impact approximately 1.5 billion shares outstanding, held by institutional and retail investors, as well as stakeholders in the healthcare sector.

Per standard SEC requirements, such filings detail key metrics like revenue, net income, and expenses, affecting valuations in the S&P 500 index where Pfizer is a component.

Prior to this filing, Pfizer's most recent financial condition for the period remained undisclosed to the public. The new submission makes available the results of operations, shifting the information from internal records to public domain effective May 5, 2026.

This updates the company's reported financial state, incorporating any changes in assets, liabilities, and equity as outlined in the attached exhibits.

The filing activates several regulatory and operational sequences. Under SEC rules, the disclosed financial statements must comply with Generally Accepted Accounting Principles, potentially prompting amendments if errors are identified within the standard correction window.

Investors and analysts will reference this data for quarterly earnings assessments, which often lead to updated Form 10-Q filings due within 45 days for large accelerated filers like Pfizer. Additionally, the information supports compliance with stock exchange listing requirements, ensuring continuous disclosure to maintain trading status on the New York Stock Exchange.

Pfizer has filed similar 8-K forms for financial results multiple times each year since its incorporation in 1942. The company last reported quarterly results in early 2026, following a pattern established under the Sarbanes-Oxley Act of 2002, which mandates prompt disclosure of material financial information.